MDXH Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 27.70
- PEG ratio
- —
- P/B
- 23.64
- P/S (TTM)
- 0.19
- EV/EBITDA
- 17.57
Profitability & growth
- ROE (TTM)
- -2440.0%
- Operating margin
- -26.7%
- Revenue growth YoY
- 12.7%
- Dividend yield
- —
- Beta
- -503341.44
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About MDxHealth SA ADR
Company profileMDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. Its leading product, ConfirmMDx for Prostate Cancer, exemplifies the company's commitment to clinical efficacy and personalized medicine, establishing a strong foothold in a rapidly growing market. As the demand for targeted cancer therapies increases, MDxHealth is poised to expand its diagnostic offerings, effectively addressing critical unmet needs in oncology and improving patient outcomes. With its innovative solutions and…
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- CAP BUSINESS CENTER, HERSTAL, BELGIUM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer